Western Digital (WDC) Moves On Evercore ISI Initiation with $130.00 Target, Alexion Pharmaceuticals (ALXN) Sentiment Is 1.07

June 19, 2017 - By Henry Gaston

Among 27 analysts covering Western Digital Corp. (NYSE:WDC), 22 have Buy rating, 1 Sell and 4 Hold. Therefore 81% are positive. Western Digital Corp. has $140 highest and $40 lowest target. $94.71’s average target is 8.71% above currents $87.12 stock price. Western Digital Corp. had 68 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Overweight” rating given on Friday, April 28 by Morgan Stanley. The stock has “Neutral” rating by Goldman Sachs on Tuesday, December 20. The rating was initiated by Mizuho on Friday, December 11 with “Neutral”. The firm has “Strong Buy” rating given on Friday, April 28 by Needham. The company was maintained on Thursday, January 26 by Maxim Group. UBS initiated Western Digital Corp (NASDAQ:WDC) rating on Thursday, September 10. UBS has “Sell” rating and $71 target. The rating was maintained by Mizuho on Friday, January 29 with “Neutral”. The rating was upgraded by Argus Research on Thursday, October 1 to “Buy”. On Wednesday, March 1 the stock rating was maintained by Cowen & Co with “Outperform”. Benchmark maintained it with “Buy” rating and $84 target in Friday, May 27 report.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $24.73 billion. The Firm is focused on the development and commercialization of therapeutic products. It has a 54.13 P/E ratio. The Company’s products include Soliris , Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Since January 9, 2017, it had 0 insider purchases, and 19 sales for $28.48 million activity. On Thursday, May 4 the insider Sivaram Srinivasan sold $3.58 million. On Monday, May 15 LONG MARK P sold $271,664 worth of Western Digital Corp (NASDAQ:WDC) or 3,034 shares. $5.27 million worth of Western Digital Corp (NASDAQ:WDC) shares were sold by MILLIGAN STEPHEN D. BHATIA MANISH H sold $2.61 million worth of stock or 34,734 shares. 21,410 Western Digital Corp (NASDAQ:WDC) shares with value of $1.86 million were sold by DeMaria Jacqueline. On Friday, June 2 the insider RAY MICHAEL CHARLES sold $48,365. Another trade for 27,137 shares valued at $2.31 million was made by CORDANO MICHAEL D on Friday, April 7.

Investors sentiment decreased to 1.11 in 2016 Q4. Its down 0.02, from 1.13 in 2016Q3. It turned negative, as 49 investors sold Western Digital Corp shares while 223 reduced holdings. 99 funds opened positions while 203 raised stakes. 235.90 million shares or 1.40% less from 239.26 million shares in 2016Q3 were reported. Texas Permanent School Fund reported 85,517 shares stake. Comerica Commercial Bank has 88,065 shares. Iridian Asset Ct has invested 1.01% in Western Digital Corp (NASDAQ:WDC). Ing Groep Nv accumulated 88,665 shares. Bluecrest Cap Management Ltd reported 0.06% of its portfolio in Western Digital Corp (NASDAQ:WDC). 1.56 million are held by Ny State Common Retirement Fund. Perkins Invest Mngmt Limited Company holds 703,413 shares. Viking Glob L P invested in 0.43% or 1.41M shares. Coastline Tru Co has 11,456 shares for 0.15% of their portfolio. 10 accumulated 172,629 shares or 3.29% of the stock. 514,018 were reported by Quentec Asset Limited Company. 195,089 were accumulated by Aviva Public Limited Company. Redwood Lc accumulated 0.94% or 153,553 shares. Amica Retiree Medical Tru has 0.12% invested in Western Digital Corp (NASDAQ:WDC). Signalpoint Asset Mgmt Limited Liability holds 0.22% or 12,702 shares.

The stock decreased 0.22% or $0.19 during the last trading session, reaching $87.12. About 28 shares traded. Western Digital Corp (NYSE:WDC) has risen 125.85% since June 19, 2016 and is uptrending. It has outperformed by 109.15% the S&P500.

Analysts await Western Digital Corp (NASDAQ:WDC) to report earnings on July, 27. They expect $2.03 earnings per share, up 156.96% or $1.24 from last year’s $0.79 per share. WDC’s profit will be $589.99 million for 10.73 P/E if the $2.03 EPS becomes a reality. After $2.07 actual earnings per share reported by Western Digital Corp for the previous quarter, Wall Street now forecasts -1.93% negative EPS growth.

Western Digital Corporation is a developer, maker and well-known provider of data storage devices and solutions that address the needs of the information technology (IT) industry and the infrastructure that enables the proliferation of data in virtually every industry. The company has market cap of $25.32 billion. The Company’s portfolio of offerings addresses three categories: Datacenter Devices and Solutions (capacity and performance enterprise hard disk drives (HDDs), enterprise solid state drives (SSDs), datacenter software and system solutions); Client Devices (mobile, desktop, gaming and digital video hard drives, client SSDs, embedded products and wafers), and Client Solutions (removable products, hard drive content solutions and flash content solutions). It currently has negative earnings.

The stock decreased 3.39% or $4 on June 16, reaching $113.98. About shares traded. Alexion Pharmaceuticals, Inc. (ALXN) has declined 18.12% since June 19, 2016 and is downtrending. It has underperformed by 34.82% the S&P500.

Ratings analysis reveals 33% of Alexion Pharma’s analysts are positive. Out of 6 Wall Street analysts rating Alexion Pharma, 2 give it “Buy”, 1 “Sell” rating, while 3 recommend “Hold”. The lowest target is $82.0 while the high is $187.0. The stock’s average target of $133.67 is 17.27% above today’s ($113.98) share price. ALXN was included in 6 notes of analysts from September 15, 2016. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Perform” rating by Oppenheimer on Thursday, December 15. As per Tuesday, December 13, the company rating was downgraded by Morgan Stanley. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Neutral” rating by Wedbush on Friday, September 23. Goldman Sachs upgraded the shares of ALXN in report on Friday, October 28 to “Buy” rating. The stock has “Underperform” rating by FBR Capital on Thursday, September 15. RBC Capital Markets maintained it with “Outperform” rating and $187.0 target in Thursday, December 22 report.

Since January 1, 0001, it had 2 insider purchases, and 25 insider sales for $220.26 million activity.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on July, 27. They expect $1.10 EPS, up 18.28% or $0.17 from last year’s $0.93 per share. ALXN’s profit will be $238.66M for 25.90 P/E if the $1.10 EPS becomes a reality. After $1.20 actual EPS reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -8.33% negative EPS growth.

Baker Bros. Advisors Lp holds 7.85% of its portfolio in Alexion Pharmaceuticals, Inc. for 6.54 million shares. Lagoda Investment Management L.P. owns 161,202 shares or 6.77% of their US portfolio. Moreover, Blue Jay Capital Management Llc has 6.65% invested in the company for 90,134 shares. The California-based Ecor1 Capital Llc has invested 6.63% in the stock. Bb Biotech Ag, a Switzerland-based fund reported 1.23 million shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: